https://www.selleckchem.com/pr....oducts/tubastatin-a.
00. Over a median follow-up period of 20.9 months, there were no significant differences between two subgroups with regard to cardiovascular death (2.8% vs. 0%, p = 0.33, stroke/transient ischemic attack (2.8% vs. 5.5%, p = 1.00, major bleeding (0% vs. 2.7%, p = 1.00 and device-related thrombus (8.3% vs. 1.4%, p = 0.104). The observed annualized thromboembolic and major bleeding events determined by Kaplan-Meier analysis decreased by 82.4% and 100% in group I, 55.9% and 75.8% in group II, respectively. LAAC is a safe and ef
Like
Comment
Share
